한글목차

본 보고서는 비알코올성 지방간염(NASH) 치료제 HPG1860의 주요 7개국(미국, EU 4개국(독일, 프랑스, 이탈리아, 스페인), 영국, 일본)의 시장 동향을 조사했으며, 치료제 개요, 작용기전, 임상개발 데이터, 관련 법규, 시판 및 개발중인 약물의 경쟁 약물과의 경쟁 분석, 국가별 시장 규모 추정 및 예측, SWOT 분석, 애널리스트의 견해 등을 정리하여 전해드립니다.

보고서 주요 내용:

• 비알코올성 지방간염(NASH) 시장 시나리오는 광범위한 연구와 의료비 지출 증가로 인해 향후 몇 년 동안 변화할 것으로 예상됩니다.
• 각 회사는 질병을 치료 및 개선하고, 과제를 평가하고, HPG1860의 우위에 영향을 미칠 수 있는 기회를 얻기 위해 새로운 접근 방식에 초점을 맞춘 치료제를 개발하고 있습니다.
• 다른 신흥 NASH 치료제가 HPG1860과 치열한 시장 경쟁을 벌일 것으로 예상되며, 가까운 시일 내에 후발 신약이 출시되면 시장에 큰 영향을 미칠 전망입니다.
• 법규상의 이정표와 개발 활동에 대한 자세한 설명을 통해 NASH에서 HPG1860의 현재 개발 시나리오를 제공합니다.
• 2024년부터 2032년까지 HPG1860의 예측 판매 데이터에 대한 상세한 분석을 통해 NASH에서 HPG1860의 전반적인 시나리오를 파악하고, 치료제 포트폴리오에 대한 의사결정 과정을 지원합니다.

목차

제1장 보고서 소개

제2장 비알코올성 지방간염(NASH)의 HPG1860 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 규제 마일스톤
• 기타 개발 활동
• 제품 프로파일

제3장 경쟁 구도(출시된 치료제)

제4장 경쟁 구도(후기 단계 신흥 치료제)

제5장 HPG1860 : 시장 평가

• NASH에 대한 HPG1860 : 시장 전망
• 주요 7개국 분석
  • NASH 치료제 HPG1860 시장 규모
• 국가별 시장 분석
  • 시장 규모 : 미국
  • 시장 규모 : 독일
  • 시장 규모 : 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 보고서 구입 옵션

영문목차

"HPG1860 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about HPG1860 for Non-alcoholic Steatohepatitis (NASH) in the seven major markets. A detailed picture of the HPG1860 for NASH in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the HPG1860 for NASH. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the HPG1860 market forecast analysis for NASH in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in NASH.

Drug Summary:

HPG1860 is an investigational potent and selective full FXR agonist with a non-bile acid scaffold. Through regulation of gene expression of bile acids, FXR serves as a key controller of bile acid homeostasis. FXR has been studied for its role in modulating inflammation, and the expression of FXR is down-regulated during NASH development. HPG1860 exhibited superb efficacy and safety in preclinical, Phase I and IIa clinical trials.

Hepagene plans to submit an abstract with detailed data from the RISE Study to an upcoming scientific conference. Based on the positive results of the Phase IIa trial, Hepagene continues with the current clinical development plan, including a combination trial of HPG1860 with HPG7233, a thyroid hormone receptor beta agonist (THR-B) developed in-house to treat NASH.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the HPG1860 description, mechanism of action, dosage and administration, research and development activities in Non-alcoholic Steatohepatitis (NASH).
• Elaborated details on HPG1860 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the HPG1860 research and development activities in NASH across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around HPG1860.
• The report contains forecasted sales of HPG1860 for NASH till 2032.
• Comprehensive coverage of the late-stage emerging therapies for NASH.
• The report also features the SWOT analysis with analyst views for HPG1860 in NASH.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

HPG1860 Analytical Perspective by DelveInsight

• In-depth HPG1860 Market Assessment

This report provides a detailed market assessment of HPG1860 for Non-alcoholic Steatohepatitis (NASH) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.

• HPG1860 Clinical Assessment

The report provides the clinical trials information of HPG1860 for Non-alcoholic Steatohepatitis (NASH) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Non-alcoholic Steatohepatitis (NASH) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence HPG1860 dominance.
• Other emerging products for NASH are expected to give tough market competition to HPG1860 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of HPG1860 in NASH.
• Our in-depth analysis of the forecasted sales data of HPG1860 from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the HPG1860 in NASH.

Key Questions:

• What is the product type, route of administration and mechanism of action of HPG1860?
• What is the clinical trial status of the study related to HPG1860 in Non-alcoholic Steatohepatitis (NASH) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the HPG1860 development?
• What are the key designations that have been granted to HPG1860 for NASH?
• What is the forecasted market scenario of HPG1860 for NASH?
• What are the forecasted sales of HPG1860 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to HPG1860 for NASH?
• Which are the late-stage emerging therapies under development for the treatment of NASH?

Table of Contents

1. Report Introduction

2. HPG1860 Overview in Non-alcoholic Steatohepatitis (NASH)

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. HPG1860 Market Assessment

• 5.1. Market Outlook of HPG1860 in Non-alcoholic Steatohepatitis (NASH)
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of HPG1860 in the 7MM for Non-alcoholic Steatohepatitis (NASH)
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of HPG1860 in the United States for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.2. Market Size of HPG1860 in Germany for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.3. Market Size of HPG1860 in France for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.4. Market Size of HPG1860 in Italy for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.5. Market Size of HPG1860 in Spain for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.6. Market Size of HPG1860 in the United Kingdom for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.7. Market Size of HPG1860 in Japan for Non-alcoholic Steatohepatitis (NASH)

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options